Navigation Links
Clexane(R)/Lovenox(R) Approved in Japan
Date:1/28/2008

PARIS, January 28 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the anticoagulant Clexane(R) (enoxaparin sodium injection) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the prevention of venous thromboembolism (VTE) in patients undergoing orthopaedic surgery of the lower limbs such as total hip replacement, total knee replacement and hip fracture surgery.

Venous thromboembolism is a frequent and preventable complication among patients hospitalized for orthopaedic surgery. Deep vein thrombosis (DVT) and pulmonary embolism are common manifestations of VTE and can significantly impact morbidity and mortality in surgical patients. The Japanese VTE guidelines state that, without prophylaxis, between 27% and 50% of orthopaedic surgery patients may suffer from deep vein thrombosis. Among the hospitalised patients at risk for VTE, 64% are those undergoing surgery(1).

"In Japan, Clexane(R) is expected to greatly contribute to the prevention of venous thromboembolism and fulfil an important medical need for patients undergoing orthopaedic surgery" said Hanspeter Spek, Executive Vice-President Pharmaceutical Operations of sanofi-aventis. "Clexane(R)'s approval illustrates the commitment of sanofi-aventis to bring new life saving drugs to patients in Japan, where further clinical trials are being conducted with Clexane(R) to extend its use to abdominal surgery patients who are at risk for venous thromboembolic complications" he added.

Outside Japan with over 200 million patients treated in more than 100 countries, Clexane(R) / Lovenox(R) (enoxaparin sodium) is the most extensively studied and most widely used low-molecular-weight heparin in the world. In venous thrombosis, Clexane(R) / Lovenox(R) is recommended by international guidelines not only in orthopaedic and general surgical patients at high and moderate risk of VTE, but also for acutely ill medical patients, and is an important tre
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
2. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
3. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
4. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
5. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
8. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
9. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
10. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
11. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, a ... editorials addressing developments and pathways related to oncological ... article exploring the role of follicle-stimulating hormone (FSH) ... prostate cancer. , The article references seminal ... there could be a connection to prostate cancer ...
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... China, May 11 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced that it will conduct a,conference call at 10:00 ... to discuss its first quarter of fiscal year 2009 ...
... DIEGO, May 11, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... quarter ended March 31, 2009. Arena reported a net loss ... of $50.6 million, or $0.68 per share, compared to a ... of 2008 of $55.0 million, or $0.75 per share. "Receiving ...
... Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the ... received approval from the Chinese State Food and ... formulation of Perindopril, an anti-hypertension drug.Perindopril, used alone ... high blood pressure, is the latest generation of ...
Cached Biology Technology:China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 8Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril 2
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... Bonn Institute for Forensic Medicine has recorded that the ... sexual offences within their catchment area increased 10-fold between ... Deutsches rzteblatt International, Burkhard Madea and Frank Musshoff ... for the most frequent substances ( Dtsch Arztebl Int ...
... should be built in Lund, Sweden, it has been announced ... last night (28 May), seven countries voted in support of ... a further two voting with the majority. The European ... for materials research, enabling scientists to study the atomic and ...
... of a USC-led research team say they,ve made a big ... and other biological materials one that may be a ... of a piece of synthetic antibody attached to a nanowire ... If the protein the antibody binds to is present in ...
Cached Biology News:Sweden to host 1.3 billion Euro research center 2A quicker, cheaper SARS virus detector -- one easily customizable for other targets 2
... RNAi Kit is optimized for ... amounts of ready-to-use dsRNA for ... The MEGAscript RNAi Kit is ... transcription technol-ogy and includes reagents ...
... actuators as building blocks, Parker can ... ,robotic solutions that are ideal for ... base ,system, Parker can also integrate ... structures, and ,guarding., Standard or ...
... is the smallest electronic pressure controller ... mm. Parker configured this unit specifically for ... markets. Used in carrier gas flow control, ... dispensing, and hydro-dynamic focusing, the OEM-EPC offers ...
...
Biology Products: